세계의 여성 건강 치료 시장 평가 : 약제별, 적응증별, 연령층별, 최종 사용자별, 지역별, 기회, 예측(2018-2032년)

Global women's health therapeutics market is projected to witness a CAGR of 4.03% during the forecast period 2025-2032, growing from USD 40.89 billion in 2024 to USD 56.07 billion in 2032F owing to a rise in gynecological issues in women, rise in cancer cases such as cervical cancer, breast cancer, colorectal cancer in women. Along with this number rising each day, women are also becoming more aware towards their own health and the possible treatment options which is giving this market a boost.

For instance, in May 2023, Precigen, Inc. announced the launch of a Phase 2 research after the FDA approved an investigatory new drug (IND) application. The first-in-class PRGN-2009 Off-the-Shelf (OTS) AdenoVerse immunotherapy will be assessed in this study in conjunction with pembrolizumab. Patients with metastatic or recurring cervical cancer are of focus.

Therapeutic Development Boosts Market Demand

New methods of drug development, such as targeted therapies, biologic products, and personalized medicine have contributed towards the growth of women's health therapeutics market. The development of treatment regimens incorporating Selective Progesterone Receptor Modulators (SPRM)s for fibroids, Gonadotropin-Releasing Hormone (GnRH) antagonists for endometriosis, and monoclonal antibodies for osteoporosis have enhanced treatment results. Adoption of long-acting reversible contraceptives (LARCs) and non-hormonal therapies for menopause also increase options for women who want safer and more effective treatments. In addition, pharmaceutical companies are creating more precision medicine products aimed at an individual's hormonal and genomic basis using artificial intelligence (AI) and genomics. Adoption of other biologics, like Denosumab for osteoporosis and immune checkpoint inhibitors for gynecological cancers, also contribute to the market growth. Innovative drug targets and new mechanisms of drug delivery are still being discovered, which will continue to change the scope of women's health therapeutics and improve patient outcomes and market growth. For instance, for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy, the FDA approved Capivasertib (Truqap, AstraZeneca Pharmaceuticals) with Fulvestrant on November 16, 2023.

Rising Incidence of Gynecological Issues Supports Market Expansion

Women's health issues like PCOS, endometriosis, and uterine fibroids are rising and is one of the primary factors driving growth in the global women health therapeutics market. Worldwide, an estimated of 8 to 13% of women that are at a childbearing age, experience PCOS, an ailment that can cause infertility as well as metabolic issues. As per the estimates of the WHO published in February 2025, Polycystic ovary syndrome (PCOS) affects approximately 6-13% of women of reproductive age. Almost 10% of the women globally, suffer from endometriosis which causes chronic pelvic pain and lower quality of life. The combination of better understanding of these disorders and improved diagnostics has increased the need for effective therapeutics. Moreover, lifestyle changes like obesity, increase in stress levels, and hormone imbalance have also deteriorated the gynecological health. To address the growing patient population, pharmaceutical companies are developing new treatment strategies which include hormonal therapy, anti-inflammatory medications, and biologic drugs. With the increased proactivity around these issues by the patients and healthcare providers, innovations in treatment and improvement in availability for women's health therapeutics are constantly on the rise.

Cancer Accounting for Significant Share of the Market

The increasing occurrence of cancer cases such as breast, ovarian and cervical cancer is one of the factors that propel the global feminine health therapeutics market. Breast cancer is still the most prevalent malignancy among women with over 2.3 million cases diagnosed every year around the globe. With the growing burden of these cases, there is greater spending in new and innovative breast and ovarian cancer treatments, including targeted therapies, immunotherapy, and hormone-based therapies. For example, breast and ovarian cancer treatment is being revolutionized with CDK4/6 and PARP inhibitors which are enhancing prognosis. These initiatives coupled with more aggressive cancer detection programs have resulted in increased diagnoses which escalates the need for effective therapeutics. Greater public and personal advocacy has resulted in many more women undergoing timely treatment which increases drug sales to the pharma companies. The development towards individualized oncology treatment will further increase the market's requirements for women's cancer therapeutics in the future and will help fulfill unaddressed medical demands.

For instance, A Phase I/II trial (NCT03665285) to assess the safety and tolerability of NC318 as a possible treatment for advanced or metastatic solid cancers was announced by NextCure, Inc. in September 2023. Evaluations for diseases such ovarian cancer, is part of the experiment.

North America Holds Major Market Share in Market

An advanced healthcare system, high levels of awareness, and robust investment in pharmaceutical R&D helps North America dominate the global women's health therapeutics market. Major pharmaceutical companies such as Pfizer, Merck, and Eli Lilly have pioneered innovation in the region and their strong presence fuels the continuous advancement in women's health therapeutics. The supportive government initiatives and reimbursement policies for contraceptives, hormone replacement therapies, and cancer treatment also greatly benefit the region. The high occurrence of endometriosis, menopause-related disorders, and osteoporosis further increases the demand for effective therapies. The adoption of cutting-edge technologies such as precision medicine and AI-based drug development has further propelled the growth of the market. Swift approval of advanced women health medicines by the U.S. FDA allows for new treatments to become available faster. The growing focus on women healthcare, coupled with increased R&D investment ensures North America retains its commanding role in the market while also leading the rest of the world in the development of innovative therapeutics.

Future Market Scenario (2025-2032F)

One of the main factors contributing to the anticipated growth of the women's health therapeutics drugs market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. Not only that but the rising population and cases of cancer is also a factor that will always propel market growth in future.

Also, players in this market are expanding at an un-paralleled rate, introducing cost-effective and efficient technologies. For instance, in June 2023, Nykode introduced its clinical trial in collaboration with F. Hoffmann-La Roche Ltd, which aimed at the examination of a combination treatment of patients with advanced cervical cancer. This therapy will be provided through a combination synergistic with Nykode VB10.16 and Tecentriq of Roche.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of women's health therapeutics and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, Ferring B.V. expanded its commitment to women's health through a strategic partnership with the BioInnovation Institute in 2023. This alliance is focused on accelerating the development of innovative solutions in the field of women's health, promising to bring new advancements and improvements to care.

For example, Pfizer Inc. made headlines in October 2023, by securing FDA approval for a pioneering maternal vaccine designed to protect infants against Respiratory Syncytial Virus (RSV). This breakthrough represents a significant advancement in maternal and infant health care.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Women's Health Therapeutics Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug
    • 4.2.1.1. ACTONEL
    • 4.2.1.2. FORTEO
    • 4.2.1.3. Mirena
    • 4.2.1.4. NuvaRing
    • 4.2.1.5. Premarin
    • 4.2.1.6. Prolia
    • 4.2.1.7. Others
  • 4.2.2. By Indication
    • 4.2.2.1. Hormonal Infertility
    • 4.2.2.2. Cancer
      • 4.2.2.2.1. Cervical Cancer
      • 4.2.2.2.2. Breast Cancer
      • 4.2.2.2.3. Colorectal Cancer
      • 4.2.2.2.4. Ovarian Cancer
      • 4.2.2.2.5. Others
    • 4.2.2.3. Contraceptives
    • 4.2.2.4. Postmenopausal Osteoporosis
    • 4.2.2.5. Endometriosis and Uterine Fibroids
    • 4.2.2.6. Menopause
    • 4.2.2.7. Polycystic Ovary Syndrome (PCOS)
    • 4.2.2.8. Others
  • 4.2.3. By Age-group
    • 4.2.3.1. Below 18
    • 4.2.3.2. 18 to 45
    • 4.2.3.3. Above 45
  • 4.2.4. By End-user
    • 4.2.4.1. Hospital Pharmacies
    • 4.2.4.2. Retail Pharmacies
    • 4.2.4.3. Online Pharmacies
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Indication
  • 4.3.2. By Age-group
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. North America Women's Health Therapeutics Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug
    • 5.2.1.1. ACTONEL
    • 5.2.1.2. FORTEO
    • 5.2.1.3. Mirena
    • 5.2.1.4. NuvaRing
    • 5.2.1.5. Premarin
    • 5.2.1.6. Prolia
    • 5.2.1.7. Others
  • 5.2.2. By Indication
    • 5.2.2.1. Hormonal Infertility
    • 5.2.2.2. Cancer
      • 5.2.2.2.1. Cervical Cancer
      • 5.2.2.2.2. Breast Cancer
      • 5.2.2.2.3. Colorectal Cancer
      • 5.2.2.2.4. Ovarian Cancer
      • 5.2.2.2.5. Others
    • 5.2.2.3. Contraceptives
    • 5.2.2.4. Postmenopausal Osteoporosis
    • 5.2.2.5. Endometriosis and Uterine Fibroids
    • 5.2.2.6. Menopause
    • 5.2.2.7. Polycystic Ovary Syndrome (PCOS)
    • 5.2.2.8. Ohers
  • 5.2.3. By Age-group
    • 5.2.3.1. Below 18
    • 5.2.3.2. 18 to 45
    • 5.2.3.3. Above 45
  • 5.2.4. By End-user
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
    • 5.2.4.4. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Women's Health Therapeutics Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Drug
        • 5.3.1.2.1.1. ACTONEL
        • 5.3.1.2.1.2. FORTEO
        • 5.3.1.2.1.3. Mirena
        • 5.3.1.2.1.4. NuvaRing
        • 5.3.1.2.1.5. Premarin
        • 5.3.1.2.1.6. Prolia
        • 5.3.1.2.1.7. Others
      • 5.3.1.2.2. By Indication
        • 5.3.1.2.2.1. Hormonal Infertility
        • 5.3.1.2.2.2. Cancer
        • 5.3.1.2.2.2.1. Cervical Cancer
        • 5.3.1.2.2.2.2. Breast Cancer
        • 5.3.1.2.2.2.3. Colorectal Cancer
        • 5.3.1.2.2.2.4. Ovarian Cancer
        • 5.3.1.2.2.2.5. Others
        • 5.3.1.2.2.3. Contraceptives
        • 5.3.1.2.2.4. Postmenopausal Osteoporosis
        • 5.3.1.2.2.5. Endometriosis and Uterine Fibroids
        • 5.3.1.2.2.6. Menopause
        • 5.3.1.2.2.7. Polycystic Ovary Syndrome (PCOS)
        • 5.3.1.2.2.8. Others
      • 5.3.1.2.3. By Age-group
        • 5.3.1.2.3.1. Below 18
        • 5.3.1.2.3.2. 18 to 45
        • 5.3.1.2.3.3. Above 45
      • 5.3.1.2.4. By End-user
        • 5.3.1.2.4.1. Hospital Pharmacies
        • 5.3.1.2.4.2. Retail Pharmacies
        • 5.3.1.2.4.3. Online Pharmacies
        • 5.3.1.2.4.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Women's Health Therapeutics Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Women's Health Therapeutics Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Women's Health Therapeutics Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Women's Health Therapeutics Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Porter's Five Forces Analysis

12. PESTLE Analysis

13. Pricing Analysis

14. Market Dynamics

• 14.1. Market Drivers
• 14.2. Market Challenges

15. Market Trends and Developments

16. Regulatory Framework and Innovation

• 16.1. Regulatory Approvals
• 16.2. Product Pipeline

17. Patent Landscape

18. Case Studies

19. Competitive Landscape

• 19.1. Competition Matrix of Top 5 Market Leaders
• 19.2. SWOT Analysis for Top 5 Players
• 19.3. Key Players Landscape for Top 10 Market Players
  • 19.3.1. Merck & Co., Inc.
    • 19.3.1.1. Company Details
    • 19.3.1.2. Key Management Personnel
    • 19.3.1.3. Products and Services
    • 19.3.1.4. Financials (As Reported)
    • 19.3.1.5. Key Market Focus and Geographical Presence
    • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 19.3.2. Pfizer Inc.
  • 19.3.3. GlaxoSmithKline plc
  • 19.3.4. F. Hoffmann-La Roche Ltd
  • 19.3.5. AbbVie Inc.
  • 19.3.6. Amgen Inc.
  • 19.3.7. Novartis AG
  • 19.3.8. Eli Lilly and Company
  • 19.3.9. Johnson & Johnson Services, Inc.
  • 19.3.10. AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer